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2Abstract
Objective: Aim of the study was to investigate the influence of CSF Aß42, p-tau and t-tau on 
cognitive functioning.
Methods: We analyzed the ability of the CSF biomarkers amyloid ß42, phosphorylated tau181 and 
total tau to predict the results on a cognitive screening test that assesses multiple cognitive 
domains (CAMCOG-R) in 65 memory clinic patients (73.1 ± 8.2 years) (n=30 probable 
Alzheimer’s disease (AD), n=7 possible AD, n=12 non-AD dementia, n=16 mild cognitive 
impairment).
Results: We found no correlations between CSF biomarkers and CAMCOG-R performance in 
the whole group, nor in subgroups based on aberrant biomarker concentrations.
Discussion: Changed concentrations of CSF amyloid ß42, p-tau and t-tau cannot be directly 
linked to cognitive function in our sample of patients with cognitive impairment. Possibly, 
compensatory mechanisms such as cognitive reserve determine cognitive performance, rather 
than the absolute amount of damage caused by Aß deposition and tangle formation. In addition, 
abnormal CSF biomarker concentrations may not be a direct reflection of the amount of neuronal 
damage, but merely serve as an indicator of AD pathology.
Conclusion: While CSF biomarkers are valuable in establishing AD pathology, they cannot be 
used to predict severity of cognitive impairment.
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Focus points
• CSF Aß42, p-tau and t-tau do not correlate with cognitive functioning in a heterogeneous 
older population with cognitive impairment.
• Abnormal CSF biomarker concentrations may not reflect the absolute amount of neuronal 
damage, but merely serve as an indicator of AD pathology.
• Clinicians should be cautious that CSF biomarkers cannot be used in isolation to predict the 
severity of cognitive impairment.
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4Introduction
Cerebrospinal fluid (CSF) biomarkers amyloid ß42 (Aß42), phosphorylated tau181 (p-tau) and total 
tau (t-tau) concentrations are altered in Alzheimer's disease (AD) patients compared to controls. 
In other types of dementia and also in part of the patients with mild cognitive impairment (MCI), 
changes in these biomarker concentrations, although less specific, have been reported.1,2,3 Aß is 
said to be neurotoxic,4 while CSF tau and p-tau are suggested to reflect neurodegeneration.5 
Likely, pathological concentrations of these proteins induce or signal neuronal damage, resulting 
in cognitive impairment.
To date, research on the correlation between CSF biomarkers and cognitive functions, 
however, shows contradicting results. In AD patients, inconsistent correlations between the Mini 
Mental State Examination (MMSE) and Aß42 have been reported.6,7,8,9 A correlation between the 
MMSE and tau was often lacking,6,7 but sometimes present.9 The MMSE is a cognitive screening 
test that is easily applicable in clinical practice, but lacks sensitivity and specificity and may be 
biased by lack of correction for educational level.10,11 This possibly explains these inconsistent 
results. A more extensive assessment of cognitive functioning may be a more valid approach to 
study the relation between CSF biomarkers and cognitive functioning. The few studies that have 
used such an extensive assessment again showed inconsistent results. In AD patients, a weak 
correlation between a paired-associate memory test and CSF p-tau and t-tau, but not Aß42, has 
been reported,12 while others failed to find a correlation between the CAMCOG, a cognitive 
measure that covers multiple domains, and CSF tau.13 In a heterogeneous group of MCI and 
dementia patients (both AD and non-AD), a correlation was found between false recognition and 
levels of CSF Aß42, but not t-tau.14
We aimed to investigate the influence of CSF Aß42, p-tau and t-tau concentrations on 
cognitive functioning. We hypothesized that changes in these CSF biomarkers reflect neuronal 
damage and directly underlie cognitive impairment. Therefore, we expect a correlation between 
CSF biomarkers and cognitive performance, irrespective of the clinical diagnosis. To test this 
hypothesis, we retrospectively investigated a heterogeneous group of memory clinic outpatients, 
using the CAMCOG-R as a multiple-domain cognitive assessment.
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6This retrospective study used the database of the memory clinic of the Radboud University 
Nijmegen Medical Centre/Alzheimer Centre Nijmegen. We included all outpatients who visited 
our memory clinic between 2005 and October 2009 and underwent lumbar puncture as part of 
their diagnostic work up. All patients had a diagnosis of either mild cognitive impairment (MCI) 
or a type of dementia (note that no lumbar punctures have been performed in participants without 
impairment on cognitive screening tests at admission to the memory clinic). We used the Revised 
Cambridge Cognitive Examination (CAMCOG-R) as a measure of cognitive functioning.15 Its 
score ranges from 0-104, with a higher score indicating a better performance. Cut-off scores 
adjusted for age and education level have been established. Performance can be divided into a 
memory and a non-memory section (maximum score 37 and 67, respectively). These sections 
have been shown to discriminate between normal aging and early AD.16 Time between lumbar 
puncture and CAMCOG-R had to be less than 3 months. CSF was collected in polypropylene 
tubes, transported at room temperature to the adjacent laboratory within 30 minutes, centrifuged 
after routine investigations, and immediately aliquoted and stored at -80 °C until analysis. Levels 
of Aß42, t-tau, and p-tau in CSF were measured using enzyme linked immunosorbent assays 
(Innogenetics, Ghent, Belgium).
Sixty-five patients (32 males) were included. Of these, 30 were eventually diagnosed with 
probable AD and 7 with possible AD according to the NINCDS-ADRDA criteria,17 16 were 
diagnosed with MCI according to the criteria of the International Working Group on Mild 
Cognitive Impairment,18 and 12 with another type of dementia (5 vascular dementia, 2
Methods
frontotemporal dementia, 3 dementia with Lewy bodies, 2 dementia of unknown cause) (see table 
1). Mean age (± SD) was 73.1 (± 8.2) years.
We used linear regression to examine the relation between CSF biomarkers and the 
performance on the CAMCOG-R. As dependent variable we used the CAMCOG-R score, related 
to the cut-off value, since this cut-off is adjusted for age and education. This relative score was 
calculated using the following formula: total score/cut-off * 100, and: (non-)memory score * 
(cut-off/maximum score). Aß42, p-tau181 and t-tau concentrations were not normally distributed 
and were log-transformed. Analyses were corrected for sex. Primary analyses included the total 
sample of 65 patients, predicting the CAMCOG-R total score and the scores on the memory and 
non-memory sections using CSF biomarkers. For secondary analyses, we divided the sample into 
subgroups based on their biomarker results to increase the likelihood of a neurodegenerative 
disorder being present. We used previously established cut-off values2 (see table 2) and reran our 
linear regression models. We did not use the clinical diagnoses for subgroup analyses, since both 
CAMCOG-R and results of CSF analyses may have influenced the diagnostic decision making, 
whereas CSF biomarker concentrations are an objective measure and therefore subgroup analyses 
based on these concentrations are more likely to yield valid results.
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8Results
Figure 1 shows the correlation between each of the CSF biomarkers and the total CAMCOG-R 
score. In the total sample including all 65 patients, neither CSF Aß42, p-tau181, t-tau, nor the p- 
tau/Aß42 ratio was a significant predictor of the total score on the CAMCOG-R. Using the 
memory score and non-memory score as dependent variables in the linear regression model did 
not change these results.
With respect to the secondary analyses, only three models of the 36 models tested showed 
a statistically significant outcome. First, in the group with an aberrant Aß42 concentration, a 
higher Aß42 was related to a higher total CAMCOG-R score (B 34.8, p=0.040). Second, in the 
group with an aberrant p-tau181 concentration, a higher t-tau was related to a lower total 
CAMCOG-R score (B -24.9, p=0.015). Last, in the group with an aberrant t-tau concentration, a 
higher t-tau was related to a lower non-memory score (B -5.9, p=0.046). All other secondary 
analyses (k=33) were not significant (data not shown).
9We investigated the correlation between CSF biomarkers and cognitive functioning as measured 
with an extensive cognitive screening instrument that covers all major cognitive domains. We did 
not find such a correlation in a heterogeneous group of patients with cognitive impairment. 
Secondary analyses in subgroups characterized by abnormal biomarker profiles did not 
convincingly change this finding.
Our results are in agreement with previous research that reported no correlation between 
the CAMCOG and CSF tau in AD patients.13 However, we did not replicate previously reported 
findings between CSF biomarkers and memory function.12,14 Memory function is validly assessed 
by the memory section of the CAMCOG-R,16 indicating that a correlation, if  present, should have 
been detected in our study. Moreover, it is remarkable that previous studies found correlations in 
the same cognitive domain but with different CSF biomarkers. That is, one found a correlation 
with p-tau and t-tau, but not with Aß42,12 while another found a correlation with Aß42, but not 
with tau.14 It is difficult to explain this discrepancy; it is unlikely that this discrepancy can be 
attributed to differences in patient samples -  only AD patients, versus a heterogeneous group of 
MCI and dementia patients, among which AD patients. Furthermore, this cannot explain why we 
did not find a correlation with Aß42 in our heterogeneous group. In addition, a large number of 
tests and analyses have been performed in these previous studies that had not been corrected for 
multiple comparisons. The reported correlations were weak to moderate at best and in one study 
possibly driven by a cluster of patients with extreme values of p-tau and t-tau.12 Consequently, it 
is possible that these previous findings are the result of a Type I error (i.e., false positive results).
Discussion
We hypothesized that changes in Aß42 and p-tau and t-tau, as measured in CSF, would 
reflect neuronal damage leading to impaired cognitive functioning. The present findings indicate 
that these changed concentrations in CSF cannot be directly linked to cognitive functioning.
There are several explanations for this. First, it may not only be the absolute amount of damage 
caused by Aß deposition and tangle formation that determines cognitive performance, but also 
compensatory mechanisms, such as inter-individual differences in cognitive reserve. Plaques and 
tangles have indeed been found in individuals with no signs of cognitive impairment during life,19 
suggesting that these individuals could somehow compensate for the neuronal damage induced 
by the plaques and tangles. Moreover, it has been shown that plaque burden is a poor correlate of 
cognitive status at the time of death.20
Alternatively, abnormal CSF biomarker concentrations may not be a direct reflection of 
neuronal damage, but merely serve as an indicator of AD pathology. For example, in prodromal 
AD, i.e. patients with MCI who developed AD at follow-up, aberrant concentrations of CSF 
biomarkers have been found.3,21 Furthermore, in patients with established dementia, 
concentrations of CSF biomarkers remained stable during follow-up, while cognitive
22,23,24performance deteriorated. ’ ’ A correlation between CSF Aß42 and post-mortem plaque burden
has been reported to be present25 as well as absent.26
In AD, it has been hypothesized that amyloid deposition reaches a plateau before clinical 
symptoms are apparent.27,5 Increased tau is suggested to develop later and to continue to increase 
during disease progression.5 According to this model, one would not expect a correlation between 
Aß42 and cognitive functioning in AD patients, but one would expect a correlation between p-tau 
and t-tau and cognitive functioning in AD patients, regardless of causality. To prevent ourselves 
from merely finding a correlation between two features of one disease, we examined a 
heterogeneous group of patients with cognitive impairment. We did not find a correlation
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between CSF biomarkers and cognitive functioning, showing that CSF biomarkers do not directly 
underlie cognitive impairment in a concentration-dependent way.
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Conclusion
Concentrations of CSF amyloid ß42, p-tau and t-tau have no clear relationship with cognitive 
functioning once cognitive decline has started. Severe cognitive impairment can be present in the 
absence of biomarker abnormality, and vice versa. Cognitive performance may be determined by 
other factors than the absolute amount of damage the brain has suffered, such as cognitive 
reserve. In addition, abnormal CSF biomarker concentrations may not reflect the amount of 
neuronal damage, but merely serve as an indicator of Alzheimer’s disease. Clinicians should be 
cautious that CSF biomarkers can be valuable in establishing AD pathology, but they cannot be 
used to predict severity of cognitive impairment. Future studies on the relation between cognitive 
function and CSF biomarkers should focus on the rate of cognitive decline over time.
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Table 1 Characteristics of total sample and of subgroups based on clinical diagnosis
Total sample Probable AD Possible AD
Other types of 
dementia
MCI
M/F 32/33 11/19 4/3 6/6 11/5
Age (y) 73.1 ± 8.2 71.5 ± 8.8 74.3 ± 8.5 76.1 ± 7.5 73.1 ± 7.5
Years of education 10.6 ± 3.8 10.4 ± 3.9 12.0 ± 4.2 11.9 ± 4.3 9.6 ± 2.8
MMSE 21.3 ± 5.2 19.2 ± 3.9 23.6 ± 6.5 19.7 ± 6.2 25.7 ± 2.9
CAMCOG-R total 67.9 ± 15.8 60.5 ± 11.7 73.6 ± 18.4 64.3 ± 18.8 82.0 ± 7.7
CAMCOG-R memory 20.2 ± 6.8 17.0 ± 4.8 22.4 ± 8.4 20.4 ± 7.7 25.2 ± 5.5
CAMCOG-R non-memory 47.7 ± 10.7 43.5 ± 8.9 51.1 ± 11.6 43.8 ± 12.4 56.8 ± 5.2
CSF Aß42 (pg/ml) 571± 225 514± 210 506 ± 66 636± 232 657 ± 264
CSF t-tau (pg/ml) 570 ± 399 706 ± 464 739± 340 334± 214 416± 250
CSF p-taux8x (pg/ml) 91 ± 47 110 ± 52 110 ± 27 55 ± 30 75 ± 33
Values are expressed as means ± SD.
AD, Alzheimer’s disease; MCI, mild cognitive impairment; Aß42, amyloid ß42; t-tau, total tau; p-tau181, 
phosphorylated tau181.
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Table 2 Characteristics of subgroups based on CSF biomarker results
Aberrant Aß42* Aberrant p-tau181* Aberrant t-tau*
All 3 biomark 
aberrant*
Diagnoses
Probable AD 19 17 23 13
Possible AD 3 6 6 3
Other dementia 4 2 4 1
MCI 7 6 8 4
M/F 14/19 16/15 21/20 10/11
Age (y) 71.3 ± 8.0 71.8 ± 8.4 71.7 ± 8.0 70.5 ± 8.8
Years of education 11.3 ± 3.9 10.8 ± 3.9 10.9 ± 3.8 11 ± 3.9
MMSE 20.8 ± 5.5 21.3 ± 6.0 21.2 ± 5.7 20.9 ± 6.1
CAMCOG-R total 65.6 ± 16.4 68.3 ± 17.5 68.2 ± 16.6 67.1 ± 17.6
CAMCOG-R memory 19.5 ± 6.4 20.2 ± 7.0 19.6 ± 7.0 19.7 ± 7.0
CAMCOG-R non-memory 46.4 ± 11.5 48.2 ± 11.8 48.6 ± 11.0 47.4 ± 11.9
CSF Aß42 (pg/ml) 410 ± 73 478± 132 515± 185 412 ± 70
CSF t-tau (pg/ml) 659± 415 881± 366 771± 374 876 ± 359
CSF p-taux8x (pg/ml) 103 ± 50 131 ± 36 116 ± 42 132 ± 36
Values are expressed as means ± SD.
AD, Alzheimer’s disease; MCI, mild cognitive impairment; Aß42, amyloid ß42; t-tau, total tau; p-tau181, 
phosphorylated tau181.
* Aberrant Aß42: < 500 pg/ml; aberrant p-tau181: >85 pg/ml; aberrant t-tau: >350 pg/ml.2
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Figure caption
Figure 1 Scatter plots of CSF biomarkers vs total CAMCOG-R score (adjusted for age and education) in 
patients with probable Alzheimer’s disease (AD), possible AD, non-AD dementia and mild cognitive 
impairment (MCI).
